List of Excipients in Branded Drug TRINTELLIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	CELLULOSE, MICROCRYSTALLINE	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	FERRIC OXIDE YELLOW	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	HYDROXYPROPYL CELLULOSE	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	HYPROMELLOSE 2910	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	MAGNESIUM STEARATE	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	MANNITOL	2031-12-30
Cardinal Health 107 LLC	TRINTELLIX	vortioxetine	55154-0256	POLYETHYLENE GLYCOL 400	2031-12-30

Trintellix Excipient Strategy and Commercial Opportunities for Vortioxetine

Last updated: August 12, 2026

Trintellix, the U.S. brand for vortioxetine hydrobromide, is an immediate-release oral tablet marketed by Takeda Pharmaceuticals and Lundbeck. Its excipient platform is conventional and potentially reproducible by generic manufacturers: a mannitol-based tablet core with microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate and magnesium stearate, combined with a protective film coat.[1] The strongest commercial opportunities are in generic development, excipient sourcing, low-dose content uniformity, film-coating efficiency, and differentiated oral formulations.

The product has no biologic component, so biosimilar competition is not relevant. The principal competitive pathway is abbreviated new drug application, or ANDA, approval under FDA standards for pharmaceutical equivalence and bioequivalence.

What is Trintellix and how does its formulation work?

Trintellix contains vortioxetine hydrobromide, a small-molecule antidepressant approved for the treatment of major depressive disorder in adults. It is supplied as immediate-release film-coated tablets in 5 mg, 10 mg, 15 mg and 20 mg strengths.[1]

Product attribute	Trintellix profile
Active ingredient	Vortioxetine hydrobromide
Dosage form	Immediate-release film-coated tablet
U.S. strengths	5 mg, 10 mg, 15 mg and 20 mg
Therapeutic category	Antidepressant
FDA approval	September 2013
Original U.S. brand name	Brintellix
Current U.S. brand name	Trintellix
Primary regulatory pathway for generics	ANDA
Biosimilar relevance	None
Typical administration	Once daily, with or without food

The tablet design prioritizes manufacturability, dose flexibility and oral stability. The low-dose 5 mg product creates the greatest formulation challenge because the active pharmaceutical ingredient represents a smaller share of total tablet mass. That increases the importance of powder blending, segregation control and assay uniformity.

What excipients are used in Trintellix tablets?

The FDA-approved product labeling identifies the principal tablet-core excipients as mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate and magnesium stearate. The film coating contains conventional coating materials, including hypromellose, polyethylene glycol and colorants.[1]

Trintellix excipient functions

Excipient or excipient class	Primary function	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Supports tablet bulk and can improve palatability relative to some sugars
Microcrystalline cellulose	Binder and dry-compression aid	Supports tablet hardness and direct-compression processing
Hydroxypropyl cellulose	Binder	Improves granule or tablet cohesion
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup after administration
Magnesium stearate	Lubricant	Reduces tooling friction and ejection force
Hypromellose	Film former	Creates the tablet-coating matrix
Polyethylene glycol	Plasticizer and coating aid	Improves coating flexibility and processing
Iron oxides and titanium dioxide	Color and opacity	Enables strength differentiation and brand appearance

The formulation uses widely available excipients rather than a rare or proprietary delivery platform. That limits the commercial value of exclusivity based solely on the tablet core. Generic manufacturers can usually access equivalent compendial materials from multiple suppliers.

Which excipients create the main development risks?

The largest technical risk is not excipient availability. It is reproducing the performance of the reference product across all strengths, particularly the 5 mg tablet.

Low-dose content uniformity

Vortioxetine is present at relatively low dose levels in the 5 mg strength. Developers must control:

• Active distribution during blending.
• Particle-size differences between vortioxetine and diluents.
• Powder segregation during transfer and compression.
• Lubricant mixing time.
• Tablet weight variation.
• Assay and dosage-unit uniformity.

Mannitol and microcrystalline cellulose can provide a robust diluent system, but particle-size distribution and bulk density must be matched closely enough to avoid segregation. A generic manufacturer may use a different grade or supplier while preserving the same functional performance. That approach requires comparative development data rather than simple substitution.

Disintegration and dissolution

Sodium starch glycolate is central to rapid tablet breakup. Excessive levels can produce swelling, while insufficient or poorly distributed material can slow disintegration. Magnesium stearate also requires control because over-lubrication can reduce wetting and delay dissolution.

For an immediate-release product, dissolution profiles across multiple pH conditions are commercially important. The development target is not only rapid release, but a profile sufficiently comparable to the reference product to support a bioequivalence strategy.

Film-coating performance

The film coat has limited direct impact on drug release if it remains thin and rapidly dispersible. It still affects:

• Tablet identification by strength.
• Moisture protection.
• Mechanical durability.
• Appearance and patient acceptance.
• Packaging-line performance.

Colorant selection also has supply-chain implications. Iron oxides and titanium dioxide are broadly available, but regional restrictions, customer preferences and supplier qualification requirements can affect formulation decisions.

What commercial opportunities exist for excipient suppliers?

The most credible opportunities are in value-added grades, technical support and supply assurance rather than ownership of a unique excipient.

Mannitol and microcrystalline cellulose

Suppliers can compete through direct-compression grades with controlled:

• Particle-size distribution.
• Flowability.
• Compressibility.
• Moisture content.
• Bulk and tapped density.

A supplier offering co-processed or engineered diluent systems could target generic vortioxetine manufacturers seeking improved 5 mg uniformity or lower compression-force requirements. The commercial case is strongest when the supplier can provide formulation support, scale-up data and regulatory documentation.

Superdisintegrants

Sodium starch glycolate suppliers can differentiate through rapid hydration, low variability and predictable dissolution performance. Cross-linked carboxymethylcellulose sodium and crospovidone may be evaluated as alternative disintegrants, although a generic formulation must demonstrate comparable quality and bioequivalence performance.

Lubricants

Magnesium stearate is a mature commodity. Commercial differentiation is more likely to come from controlled specific surface area, low heavy-metal content, consistent fatty-acid profile and technical assistance with blending. Alternative lubricants could be explored for manufacturers facing dissolution sensitivity or processing constraints.

Film-coating systems

Ready-to-use coating systems can reduce development and manufacturing complexity. Opportunities include:

• Pre-blended hypromellose systems.
• Low-weight-gain coatings.
• Titanium-dioxide-free formulations.
• Color systems compatible with global regulatory requirements.
• Faster drying and lower energy consumption.
• Coatings optimized for high-speed tablet lines.

The strongest customer proposition is reduced process development time and lower batch-to-batch appearance variation.

What formulation opportunities exist beyond the reference tablet?

The reference product is an immediate-release tablet, leaving room for line extensions if clinical and regulatory requirements support them.

Orally disintegrating tablets

An orally disintegrating vortioxetine product could target patients with swallowing difficulties or adherence challenges. Mannitol, crospovidone and taste-masking technologies are potential building blocks. The key technical barrier is taste. Vortioxetine’s sensory profile would need evaluation through drug-resin complexes, polymer coatings, lipid barriers or sweetener-flavor systems.

Sprinkle or dispersible formulations

A formulation that can be dispersed in water or administered with soft food could offer a differentiated administration option. Such a product would require control of dose recovery, uniform dispersion, stability after reconstitution and compatibility with food matrices.

Modified-release products

Modified release is less commercially direct because Trintellix is already administered once daily. A sustained-release product would require a clinical rationale and could face additional pharmacokinetic and safety requirements. The opportunity is therefore weaker than for orally disintegrating or flexible-administration products.

Pediatric or geriatric dosage forms

A liquid, mini-tablet or dispersible formulation could expand use in populations that cannot reliably swallow conventional tablets. These products would require careful dose flexibility and stability work. The commercial opportunity depends on approved labeling and market access, not on excipient selection alone.

How strong is the excipient-based patent position for Trintellix?

The excipient position appears weaker than the active-ingredient and therapeutic-use positions because the commercial tablet uses conventional excipients and a conventional immediate-release architecture. A generic manufacturer would generally seek to avoid copying any claim that requires a specific composition, manufacturing process or performance limitation.

Potential IP categories include:

1. Vortioxetine chemical composition and salts.
2. Pharmaceutical compositions containing vortioxetine.
3. Methods of treating depression or related disorders.
4. Polymorph, crystal-form or solid-state claims.
5. Manufacturing processes.
6. Specific excipient combinations or dissolution profiles.
7. Formulations designed for alternative administration.

A formulation patent can be commercially relevant even when the excipients themselves are off-patent. Its value depends on claim scope, validity, written-description support, enablement, prosecution history and whether a generic product would necessarily practice the claims.

When does Trintellix lose exclusivity?

Trintellix’s market protection must be separated into FDA regulatory exclusivity, Orange Book patent protection and non-U.S. rights. FDA approval occurred in 2013, and any five-year new chemical entity exclusivity has expired. The remaining barriers are primarily patent-related, regulatory-development related and commercial.

Protection category	Trintellix status
New chemical entity exclusivity	Expired
ANDA pathway	Available in principle after applicable patent and exclusivity barriers
Biosimilar pathway	Not applicable
Orange Book patents	Must be assessed by current FDA listing and patent certifications
Method-of-use patents	May affect labeling and Paragraph IV strategy
Formulation patents	Must be evaluated claim by claim
Pediatric exclusivity	Requires confirmation from FDA records
International exclusivity	Varies by jurisdiction

The FDA Orange Book remains the controlling source for listed patents and use codes in the United States.[2] Patent expiration dates should be assessed against the specific patent, terminal disclaimer, patent-term adjustment and any applicable pediatric extension.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant can submit a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The reference sponsor may then file patent litigation within the statutory period, potentially triggering a 30-month stay under the Hatch-Waxman framework.[3]

Generic entry scenarios

Scenario	Commercial effect
No challenge before key patent expiry	Entry follows patent expiry or settlement terms
Paragraph IV challenge with no litigation	Faster potential approval, subject to other barriers
Paragraph IV litigation and 30-month stay	Delays FDA approval or commercial launch
Settlement with licensed entry	Entry occurs on an agreed date, sometimes with supply terms
Carve-out for method-of-use patent	Generic launches with restricted labeling
Multiple ANDA filers	Possible 180-day first-filer dynamics and early price erosion

The largest generic risk typically arrives when several ANDA applicants target the same molecule. Competition can reduce pricing rapidly after the first commercial launch, especially for an antidepressant with established therapeutic substitution.

No biosimilar risk applies because vortioxetine is a chemically synthesized small molecule. The relevant competitors are generic vortioxetine tablets and any authorized generic or licensed generic arrangement.

What is the Orange Book and litigation status of Trintellix?

FDA’s Drugs@FDA and Orange Book databases should be used to identify the current reference-listed drug, active ingredient, dosage forms, listed patents and use codes.[2] Litigation status must be tracked through federal court dockets and FDA patent-certification records because Orange Book listings do not provide a complete commercial history of settlements or launch agreements.

Key litigation questions include:

• Whether any listed patent has been challenged under Paragraph IV.
• Whether the sponsor filed an infringement action.
• Whether a 30-month stay was triggered.
• Whether the parties executed a settlement.
• Whether the settlement permits an earlier authorized or licensed generic launch.
• Whether a generic applicant used a section viii statement to omit patented indications.

A reliable investment assessment requires current docket and Orange Book review. Patent status can change after regulatory approval, litigation, terminal-disclaimer analysis or settlement.

How does Trintellix compare with competing antidepressants?

Trintellix competes with generic selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, including escitalopram, sertraline, fluoxetine, duloxetine and venlafaxine. Its commercial differentiation depends on prescriber preference, tolerability, formulary position and branded product support rather than a novel excipient system.

Product	Active ingredient	Dosage-form competition	Biosimilar risk	Excipient opportunity
Trintellix	Vortioxetine	Generic immediate-release tablets	None	Low-to-moderate
Lexapro	Escitalopram	Mature generic tablets and liquids	None	Low
Cymbalta	Duloxetine	Delayed-release capsules	None	Moderate, especially enteric systems
Viibryd	Vilazodone	Immediate-release tablets	None	Moderate
Auvelity	Dextromethorphan/bupropion	Extended-release tablets	None	Higher due to combination and release design

The most attractive excipient opportunity is not necessarily the branded product’s existing formulation. It may be a differentiated generic or specialty product that improves administration, taste, dose flexibility or manufacturing robustness.

What manufacturing and supply-chain barriers matter?

The active ingredient is the principal strategic input, but excipient control remains important for generic launch timing. Manufacturers should qualify at least two sources for critical materials where feasible and maintain regulatory files covering compendial compliance, residual solvents, elemental impurities, nitrosamine risk and change-control history.

Important manufacturing controls include:

• Blend uniformity for the 5 mg strength.
• Lubrication time and magnesium stearate distribution.
• Tablet hardness and friability.
• Disintegration and dissolution.
• Coating weight gain and color uniformity.
• Moisture protection during packaging.
• Stability under long-term and accelerated conditions.
• Supplier change notification and comparability.

The use of common excipients lowers supply risk, but it also reduces product differentiation. A supplier’s competitive advantage must come from performance consistency, regulatory support or lower total manufacturing cost.

What licensing opportunities exist for Trintellix formulations?

Potential licensing structures include:

• Excipient supply agreements with generic manufacturers.
• Co-development of an orally disintegrating or dispersible formulation.
• Technology licensing for taste masking.
• Contract development and manufacturing of film-coated tablets.
• Regional licensing of a differentiated dosage form.
• Authorized-generic supply arrangements.
• Formulation patent licenses where a third party controls a non-infringing delivery platform.

A successful licensing proposition should link the excipient or formulation technology to a measurable outcome: lower compression force, improved dose uniformity, faster dissolution, reduced coating time, longer stability or a clinically meaningful administration advantage.

Key Takeaways

• Trintellix is an immediate-release vortioxetine hydrobromide tablet available in four U.S. strengths.
• Its core excipient system is conventional and includes mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate and magnesium stearate.
• The 5 mg strength creates the greatest content-uniformity and segregation risk.
• Excipient-based opportunities are strongest in engineered direct-compression grades, superdisintegrants, film-coating systems and taste-masking technologies.
• Generic competition, not biosimilar competition, is the primary market risk.
• FDA Orange Book listings and federal court records are required to determine current patent challenges, litigation, settlements and launch timing.
• The strongest differentiated-product opportunities are orally disintegrating, dispersible, sprinkle or flexible-dose formulations.
• Common excipients reduce supply-chain barriers but limit standalone formulation exclusivity.

FAQs

Can a generic manufacturer use the same excipients as Trintellix?

Yes. Excipients are generally available for use by generic manufacturers, subject to regulatory quality requirements and the need to avoid infringing formulation or process claims.

Is vortioxetine subject to biosimilar competition?

No. Vortioxetine is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than biosimilar approval.

Which Trintellix strength presents the greatest formulation challenge?

The 5 mg tablet typically presents the greatest challenge because the low active dose increases sensitivity to blending, segregation and content-uniformity variation.

Is an orally disintegrating vortioxetine product commercially attractive?

It could be attractive if it improves swallowing, adherence or dose administration. Taste masking, stability, dose recovery and clinical or regulatory requirements determine commercial feasibility.

Can an excipient supplier obtain exclusivity for a Trintellix generic formulation?

Potentially, but exclusivity would usually depend on a patentable composition, process or performance feature. Commodity excipient supply alone generally does not create durable market exclusivity.

References

1. U.S. Food and Drug Administration. (2023). Trintellix (vortioxetine) tablets prescribing information. Takeda Pharmaceuticals America, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204447s016lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple first applicants are eligible for 180-day exclusivity. https://www.fda.gov/media/102628/download